Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SMMT |
---|---|---|
09:32 ET | 11538 | 7.9 |
09:34 ET | 5524 | 7.9199 |
09:36 ET | 7204 | 7.8068 |
09:38 ET | 1800 | 7.8 |
09:39 ET | 4457 | 7.87 |
09:41 ET | 800 | 7.81 |
09:43 ET | 3555 | 7.87 |
09:45 ET | 20725 | 7.92 |
09:48 ET | 10152 | 7.94 |
09:50 ET | 2240 | 7.85 |
09:52 ET | 4533 | 7.9 |
09:54 ET | 7355 | 7.96 |
09:56 ET | 27550 | 7.93 |
09:57 ET | 6006 | 7.96 |
09:59 ET | 1324 | 7.94 |
10:01 ET | 2859 | 7.96 |
10:03 ET | 15058 | 7.97 |
10:06 ET | 68347 | 7.98 |
10:08 ET | 6248 | 7.92 |
10:10 ET | 4173 | 7.93 |
10:12 ET | 13243 | 7.9 |
10:14 ET | 6070 | 7.94 |
10:15 ET | 3016 | 7.8987 |
10:17 ET | 2043 | 7.9 |
10:19 ET | 2389 | 7.9 |
10:21 ET | 11405 | 7.84 |
10:24 ET | 15100 | 7.9 |
10:26 ET | 7602 | 7.95 |
10:28 ET | 8760 | 8.015 |
10:30 ET | 34904 | 8.0521 |
10:32 ET | 16820 | 8 |
10:33 ET | 4246 | 8 |
10:35 ET | 6141 | 8.01 |
10:37 ET | 19106 | 8.095 |
10:39 ET | 4976 | 8.085 |
10:42 ET | 6309 | 8.12 |
10:44 ET | 11970 | 8.1405 |
10:46 ET | 3734 | 8.15 |
10:48 ET | 4008 | 8.165 |
10:50 ET | 3211 | 8.16 |
10:51 ET | 25446 | 8.18 |
10:53 ET | 12923 | 8.17 |
10:55 ET | 21110 | 8.1926 |
10:57 ET | 1848 | 8.19 |
11:00 ET | 601 | 8.19 |
11:02 ET | 5079 | 8.16 |
11:04 ET | 2500 | 8.13 |
11:06 ET | 11151 | 8.14 |
11:08 ET | 32890 | 8.09 |
11:09 ET | 23784 | 8.035 |
11:11 ET | 24638 | 7.972 |
11:13 ET | 7547 | 8.03 |
11:15 ET | 1344 | 8.025 |
11:18 ET | 16132 | 8.07 |
11:20 ET | 8626 | 8.06 |
11:22 ET | 838 | 8.07 |
11:24 ET | 564 | 8.055 |
11:26 ET | 2620 | 8.08 |
11:27 ET | 2625 | 8.025 |
11:29 ET | 3098 | 8.01 |
11:31 ET | 6692 | 8.03 |
11:33 ET | 9223 | 8.035 |
11:36 ET | 1700 | 8.0369 |
11:38 ET | 24727 | 7.98 |
11:40 ET | 12105 | 8 |
11:42 ET | 8892 | 7.96 |
11:44 ET | 1314 | 7.975 |
11:45 ET | 5175 | 8.05 |
11:47 ET | 6764 | 8.025 |
11:49 ET | 2700 | 8.01 |
11:51 ET | 16745 | 7.975 |
11:54 ET | 2357 | 7.94 |
11:56 ET | 3434 | 7.96 |
11:58 ET | 6650 | 7.9399 |
12:00 ET | 1588 | 7.93 |
12:02 ET | 5378 | 7.91 |
12:03 ET | 3232 | 7.95 |
12:05 ET | 1500 | 7.93 |
12:07 ET | 4753 | 7.92 |
12:09 ET | 1973 | 7.93 |
12:12 ET | 2070 | 7.94 |
12:14 ET | 4581 | 7.92 |
12:16 ET | 3662 | 7.89 |
12:18 ET | 6426 | 7.93 |
12:20 ET | 815 | 7.93 |
12:21 ET | 500 | 7.92 |
12:23 ET | 4600 | 7.91 |
12:25 ET | 1952 | 7.9 |
12:27 ET | 5251 | 7.9 |
12:30 ET | 1147 | 7.89 |
12:32 ET | 3699 | 7.88 |
12:34 ET | 2574 | 7.86 |
12:36 ET | 1922 | 7.865 |
12:38 ET | 8047 | 7.83 |
12:39 ET | 6450 | 7.885 |
12:41 ET | 2100 | 7.895 |
12:43 ET | 5995 | 7.91 |
12:45 ET | 2045 | 7.88 |
12:48 ET | 8852 | 7.91 |
12:50 ET | 1918 | 7.9 |
12:52 ET | 3400 | 7.89 |
12:54 ET | 4750 | 7.89 |
12:56 ET | 2935 | 7.89 |
12:57 ET | 2941 | 7.88 |
12:59 ET | 2533 | 7.88 |
01:01 ET | 400 | 7.895 |
01:03 ET | 6664 | 7.84 |
01:06 ET | 6406 | 7.85 |
01:08 ET | 813 | 7.855 |
01:10 ET | 5239 | 7.83 |
01:12 ET | 4480 | 7.82 |
01:14 ET | 5236 | 7.87 |
01:15 ET | 6298 | 7.84 |
01:17 ET | 1975 | 7.8404 |
01:19 ET | 700 | 7.85 |
01:21 ET | 7490 | 7.825 |
01:24 ET | 719 | 7.825 |
01:26 ET | 23108 | 7.7822 |
01:28 ET | 4412 | 7.8 |
01:30 ET | 13435 | 7.77 |
01:32 ET | 2800 | 7.76 |
01:33 ET | 2272 | 7.77 |
01:35 ET | 2956 | 7.76 |
01:37 ET | 6181 | 7.77 |
01:39 ET | 2257 | 7.752 |
01:42 ET | 11346 | 7.74 |
01:44 ET | 2736 | 7.73 |
01:46 ET | 16236 | 7.74 |
01:48 ET | 12667 | 7.73 |
01:50 ET | 8828 | 7.735 |
01:51 ET | 4915 | 7.77 |
01:53 ET | 1743 | 7.76 |
01:55 ET | 16974 | 7.7644 |
01:57 ET | 3247 | 7.78 |
02:00 ET | 2786 | 7.78 |
02:02 ET | 4778 | 7.77 |
02:04 ET | 3905 | 7.76 |
02:06 ET | 9704 | 7.82 |
02:08 ET | 8172 | 7.8 |
02:09 ET | 4587 | 7.78 |
02:11 ET | 7648 | 7.795 |
02:13 ET | 900 | 7.825 |
02:15 ET | 3614 | 7.8599 |
02:18 ET | 600 | 7.86 |
02:20 ET | 5292 | 7.86 |
02:22 ET | 978 | 7.85 |
02:24 ET | 6305 | 7.86 |
02:26 ET | 3115 | 7.86 |
02:27 ET | 3736 | 7.85 |
02:29 ET | 4134 | 7.885 |
02:31 ET | 6200 | 7.9 |
02:33 ET | 2051 | 7.9 |
02:36 ET | 5264 | 7.89 |
02:38 ET | 7911 | 7.91 |
02:40 ET | 4303 | 7.91 |
02:42 ET | 16913 | 7.9 |
02:44 ET | 11955 | 7.89 |
02:45 ET | 11635 | 7.855 |
02:47 ET | 1991 | 7.86 |
02:49 ET | 10097 | 7.86 |
02:51 ET | 15681 | 7.855 |
02:54 ET | 4830 | 7.85 |
02:56 ET | 11950 | 7.89 |
02:58 ET | 4113 | 7.87 |
03:00 ET | 4891 | 7.85 |
03:02 ET | 5381 | 7.84 |
03:03 ET | 11872 | 7.84 |
03:05 ET | 2085 | 7.83 |
03:07 ET | 2800 | 7.83 |
03:09 ET | 5568 | 7.83 |
03:12 ET | 7462 | 7.865 |
03:14 ET | 3554 | 7.86 |
03:16 ET | 5538 | 7.855 |
03:18 ET | 9783 | 7.855 |
03:20 ET | 10747 | 7.845 |
03:21 ET | 6348 | 7.835 |
03:23 ET | 6169 | 7.81 |
03:25 ET | 14039 | 7.805 |
03:27 ET | 9741 | 7.83 |
03:30 ET | 6006 | 7.82 |
03:32 ET | 5007 | 7.79 |
03:34 ET | 12929 | 7.815 |
03:36 ET | 7500 | 7.79 |
03:38 ET | 8258 | 7.79 |
03:39 ET | 7473 | 7.8 |
03:41 ET | 17094 | 7.815 |
03:43 ET | 13744 | 7.8 |
03:45 ET | 18699 | 7.82 |
03:48 ET | 6559 | 7.83 |
03:50 ET | 12722 | 7.825 |
03:52 ET | 22620 | 7.815 |
03:54 ET | 11733 | 7.79 |
03:56 ET | 38169 | 7.76 |
03:57 ET | 30384 | 7.795 |
03:59 ET | 55871 | 7.8 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Summit Therapeutics Inc | 5.6B | -47.1x | --- |
Viking Therapeutics Inc | 5.6B | -54.2x | --- |
Madrigal Pharmaceuticals Inc | 5.9B | -11.6x | --- |
BridgeBio Pharma Inc | 5.2B | -8.4x | --- |
Cytokinetics Inc | 6.0B | -9.6x | --- |
Nuvalent Inc | 5.0B | -32.5x | --- |
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.6B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 702.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.98 |
EPS | $-0.17 |
Book Value | $0.11 |
P/E Ratio | -47.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.